Other combined episignatures, such as for the BAFopathy (genes: ARID1A, ARID1B, SMARCB1, SMARCA2 and SMARCA4) episignature, are already proving their clinical utility (Aref-Eshghi et al. 2018b). This evidence concerns the gene SMARCB1 and BAFopathy.